What is the optimal induction strategy for older patients?

Best Practice and Research: Clinical Haematology

Volumn 24, Issue 4, 2011, Pages 515-522

  Estey, Elihu ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

acute myeloid leukemia; age; induction; older

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; IDARUBICIN; LENALIDOMIDE; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL TRIAL (TOPIC); DRUG INDICATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GERIATRIC PATIENT; GROUPS BY AGE; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 82355161562     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2011.09.007     Document Type: Review

References (23)

1. H. Becker, G. Marcucci, and K. Maharry Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study J Clin Oncol 28 4 2010 596 604
2. J.V. Malfuson, A. Etienne, and P. Turlure Acute Leukemia French Association (ALFA). Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia Haematologica 93 12 2008 1806 1813
3. K. Wheatley, C.L. Brookes, and A.J. Howman United Kingdom National cancer Research Institute Haematological Oncology clinical Studies group and acute myeloid leukaemia Subgroup. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials Br J Haematol 145 5 2009 598 605
4. G. Juliusson, P. Antunovic, and A. Derolf Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Blood 113 18 2009 4179 4187
5. H. Kantarjian, F. Ravandi, and S. O'Brien Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia Blood 116 22 2010 4422 4429
6. U. Krug, C. Röllig, and A. Koschmieder German Acute Myeloid Leukaemia Cooperative Group and Study Alliance Leukemia Investigators. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes Lancet 376 9757 2010 2000 2008
7. B.C. Medeiros, M. Othus, and M. Fang Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience Blood 116 13 2010 2224 2228
8. J. Menzin, K. Lang, and C.C. Earle The outcomes and costs of acute myeloid leukemia among the elderly Arch Intern Med 162 14 2002 1597 1603 (Pubitemid 34773427)
9. M.A. Sekeres, P. Elson, and M.E. Kalaycio Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients Blood 113 1 2009 28 36
10. F.R. Appelbaum, H. Gundacker, and D.R. Head Age and acute myeloid leukemia Blood 107 9 2006 3481 3485
11. E.H. Estey, Y. Shen, and P.F. Thall Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB Blood 95 1 2000 72 77 (Pubitemid 30017227)
12. M. Yanada, G. Garcia-Manero, and G. Borthakur Relapse and death during first remission in acute myeloid leukemia Haematologica 93 4 2008 633 634 (Pubitemid 351559358)
13. H. Tilly, S. Castaigne, and D. Bordessoule Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly J Clin Oncol 8 2 1990 272 279 (Pubitemid 20056558)
14. R.B. Walter, H.M. Kantarjian, and X. Huang Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study J Clin Oncol 28 10 2010 1766 1771
15. M. de Lima, S.S. Strom, and M. Keating Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work Blood 90 12 1997 4719 4724 (Pubitemid 28007184)
16. T.A. Fehniger, G.L. Uy, and K. Trinkaus A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia Blood 117 6 2011 1828 1833
17. M.A. Sekeres, H. Gundacker, and J. Lancet A phase II study of lenalidomide for previously untreated deletion (del) 5q acute myeloid leukemia (AML) patients age 60 or older who are not candidates for remission induction chemotherapy (Southwest Oncology Group Study S0605) Blood (ASH Annual Meeting Abstracts) 116 21 2010 150 (abstr 332)
18. A.F. Cashen, G.J. Schiller, and M.R. O'Donnell Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia J Clin Oncol 28 4 2010 556 561
19. P. Fenaux, G.J. Mufti, and E. Hellström-Lindberg Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia J Clin Oncol 28 4 2010 562 569
20. S.R. Mohan, A. Fu, R.V. Tiu, and E. Copelan Prior therapy with DNA methyltransferase inhibitors (DNMTI) predicts for lower remission rates and worse survival in secondary acute myeloid leukemia patients (sAML) receiving remission induction therapy Blood (ASH Annual Meeting Abstracts) 116 21 2010 1644 (abstr 4033)
21. C. Bello, D. Yu, and R.S. Komrokji Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome Cancer 117 7 2011 1463 1469
22. P. Thall, and E. Estey Graphical methods for evaluating covariate effects in the Cox model J. Crowley, Handbook of statistics in clinical oncology 2001 Marcel-Dekker New York, NY 411 433
23. R.B. Walter, M. Othus, and G. Borthakur Quantitative effect of age in predicting empirically-defined treatement-related mortality and resistance in newly diagnosed A: case against age alone as primary determinant of treatment assignment Blood (ASH Annual Meeting Abstracts) 116 21 2010 904 (abstr 2191)